Trials / Not Yet Recruiting
Not Yet RecruitingNCT04657965
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
Clinical Trial for the Safety and Efficacy of Sequential of LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies
Detailed description
This is a single arm, open-label, single-center study. This study is indicated for LMP1 positive infectious diseases and hematological malignancies. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 144 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LMP1 CAR T-cells | Each subject receive LMP1 CAR T-cells by intravenous infusion |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2024-01-15
- Completion
- 2027-01-15
- First posted
- 2020-12-08
- Last updated
- 2020-12-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04657965. Inclusion in this directory is not an endorsement.